Description
This product is a linearized polyethyleneimine (Polyethylenimine Linear, PEI) specially developed for the large-scale production of AAV in suspension culture systems. It is a chemically synthesized product, free of animal-derived components, with low cytotoxicity. The product is provided in sterile liquid form and has a wide applicability for various AAV serotypes. It features strong DNA loading capacity, low transfection complex ratio, and high complex stability, facilitating large-scale AAV production.
Features
Doubled Full Capsid Ratio
Greater Transfection Efficiency: Delivers 50% higher efficiency compared to top PEI.
Half input volume for equivalent transfection efficiency.
Lower cost
Applications
Production of AAV Viral Vectors
Specifications
|
Form |
liquid |
|
Properties |
Polyethylenimine Linear (PEI) |
|
Virus Type |
AAV |
Components
|
Components No. |
Name |
40823ES01 |
40823ES03 |
40823ES10 |
40823ES60 |
|
40823 |
Hieff Trans™ UltraAAV Transfection Reagent |
100 μL |
1 mL |
10 mL |
100 mL |
Shipping and Storage
Hieff Trans™ UltraAAV Transfection Reagent products should be stored at 2-8℃ for 2 year.
Figures
Figure 1. Hieff Trans™ UltraAAV showing low inputs. The AAV9 was produced in suspension 293F cells with different input of Hieff Trans PEI AAV (Left, Plasmids input: 0.5 μg) or Plasmids (Right, Hieff trans PEI input 0.6 μL) dosages per million cells. The virus was harvested 72 hours post-transfection.
Figure 2. When UltraAAV and Fector VIR transfection reagents were used simultaneously for AAV9 virus packaging, UltraAAV demonstrated significantly higher viral full-capsid rates (tested on viral stock) at DNA-to-PEI ratios of 1:0.5 and 1:1. Notably, when the UltraAAV reagent dosage was halved, full-capsid rate were significantly superior to Fector VIR.
Figure 3. Hieff Trans™ UltraAAV showing ultra trans-effciency compared with top PEIs. AAV2, AAV5, AAV8, and AAV9 were produced in suspension 293F cells, with a DNA dosage of 1 µg per million cells. The virus was harvested 72 hours post-transfection, and the viral supernatant was analyzed.
Related Reading
Revolutionary PEI-Mediated Gene Delivery for Superior Transfection Efficiency
Documents:
Safety Data Sheet
Manuals
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.